
Regeneron Pharmaceuticals, Inc.
REGNHealthcare|Biotechnology|US
$904.35
+1.45 (+0.16%)
DCF Value
$2028.80
Tangible Book / Share
$316.45
Graham Number
$592.50
Cash / Share
$91.46
Next Earnings Report
Jan 28, 2027
EPS est. $25.39 · Revenue est. $5.85B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (125)
Dec 2026
Est. completion
P1P2Prostate Cancer
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
NCT04989946n=57
Dec 2026
Est. completion
Dec 2026
Est. completion
P2Carcinoma, Non-Small-Cell Lung
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
NCT06623656n=112
Dec 2026
Est. completion
P2Non-Transfusion Dependent Beta-Thalassemia (NTDT)
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
NCT06421636n=19
Dec 2026
Est. completion
P1Healthy Volunteers With Hyperlipidemia
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
NCT06452771n=59
Dec 2026
Est. completion
P2Asthma
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
NCT05347771n=240
Feb 2027
Est. completion
P1Healthy Volunteer
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults
NCT07526116n=88
Feb 2027
Est. completion
P2Atrial Fibrillation (AF)
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
NCT07175428n=1,200
Feb 2027
Est. completion
P3Chronic Rhinosinusitis With Nasal Polyps
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
NCT07424144n=59
Feb 2027
Est. completion
P1Overweight or Obesity
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
NCT07594093n=90
Mar 2027
Est. completion
P4Asthma
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287n=1,339
Mar 2027
Est. completion
P3Melanoma
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916n=560
Mar 2027
Est. completion
Chronic Rhinosinusitis With Nasal Polyposis
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
NCT04959448n=717
Mar 2027
Est. completion
Mar 2027
Est. completion
Dermatitis Atopic
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
NCT03992417n=955
Apr 2027
Est. completion
P1End-Stage Kidney Disease (ESKD)
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
NCT07759167n=36
Apr 2027
Est. completion
P4Dermatitis Atopic
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
NCT05983068n=48
Apr 2027
Est. completion
P2Colon Cancer
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
NCT05961709n=50
May 2027
Est. completion
P1P2Recurrent Ovarian Cancer
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT03564340n=890
May 2027
Est. completion
P2Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma
NCT06448026n=17
Awaiting Results (20)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2026
P2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
NCT07431086Nov 2026
P1P2
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
NCT04626635Nov 2026
P2
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951Nov 2026
P2
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
NCT03951831Sep 2026
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
NCT06415175Sep 2026
P3
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Sep 2026
P3
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Aug 2026
P2
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441Recent Press Releases
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Nov 8, 2026 · GlobeNewsWire
Regeneron Announces Investor Conference Presentations
Nov 2, 2026 · GlobeNewsWire
Regeneron Reports Third Quarter 2026 Financial and Operating Results
Oct 30, 2026 · GlobeNewsWire
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Oct 26, 2026 · GlobeNewsWire
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Oct 25, 2026 · GlobeNewsWire
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Oct 16, 2026 · GlobeNewsWire
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Oct 12, 2026 · GlobeNewsWire
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Oct 6, 2026 · GlobeNewsWire
SEC Filings (47)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 5, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Oct 30, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Oct 30, 2026 | 8-K | Material event | DocumentIndex |
| Oct 6, 2026 | 8-K | Material event | DocumentIndex |
| Sep 30, 2026 | 8-K | Material event | DocumentIndex |
| Aug 20, 2026 | N-PX | DocumentIndex | |
| Aug 7, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Jul 30, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Jul 30, 2026 | 8-K | Material event | DocumentIndex |
| Jul 6, 2026 | 8-K | Material event | DocumentIndex |
| Jun 17, 2026 | 8-K | Material event | DocumentIndex |
| May 8, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Apr 30, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 29, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Apr 29, 2026 | 8-K | Material event | DocumentIndex |
| Apr 24, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 24, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 24, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Apr 8, 2026 | 8-K | Material event | DocumentIndex |
| Mar 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 6, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Feb 4, 2026 | 10-K | Annual report | DocumentIndex |
| Jan 30, 2026 | 8-K | Material event | DocumentIndex |
| Jan 12, 2026 | 8-K | Material event | DocumentIndex |
| Nov 7, 2025 | 13F-HR | Institutional holdings report | DocumentIndex |
| Oct 28, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Oct 28, 2025 | 8-K | Material event | DocumentIndex |
| Oct 6, 2025 | 8-K | Material event | DocumentIndex |
| Aug 6, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 1, 2025 | 13F-HR | Institutional holdings report | DocumentIndex |
| Aug 1, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Aug 1, 2025 | 8-K | Material event | DocumentIndex |
| Jun 18, 2025 | 8-K | Material event | DocumentIndex |
| Jun 5, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 2, 2025 | 13F-HR | Institutional holdings report | DocumentIndex |
| Apr 29, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Apr 29, 2025 | 8-K | Material event | DocumentIndex |
| Apr 29, 2025 | ARS | Annual report to holders | DocumentIndex |
| Apr 29, 2025 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 29, 2025 | DEF 14A | Proxy / shareholder vote | DocumentIndex |